[Social Security and district psychiatry].

L. Dreyfuss,R. Amiel,E. Hanon,L. Thennevier,M. Windisch

1979-03-01

Annales Medico-Psychologiques

Abstract:

What problem does this paper attempt to address?

CRISPR/Cas-based gene editing in therapeutic strategies for beta-thalassemia

Shujun Zeng,Shuangyin Lei,Chao Qu,Yue Wang,Shuzhi Teng,Ping Huang

DOI: https://doi.org/10.1007/s00439-023-02610-9

Abstract:Beta-thalassemia (β-thalassemia) is an autosomal recessive disorder caused by point mutations, insertions, and deletions in the HBB gene cluster, resulting in the underproduction of β-globin chains. The most severe type may demonstrate complications including massive hepatosplenomegaly, bone deformities, and severe growth retardation in children. Treatments for β-thalassemia include blood transfusion, splenectomy, and allogeneic hematopoietic stem cell transplantation (HSCT). However, long-term blood transfusions require regular iron removal therapy. For allogeneic HSCT, human lymphocyte antigen (HLA)-matched donors are rarely available, and acute graft-versus-host disease (GVHD) may occur after the transplantation. Thus, these conventional treatments are facing significant challenges. In recent years, with the advent and advancement of CRISPR (clustered regularly interspaced short palindromic repeats)/Cas9 (CRISPR-associated protein 9) gene editing technology, precise genome editing has achieved encouraging successes in basic and clinical studies for treating various genetic disorders, including β-thalassemia. Target gene-edited autogeneic HSCT helps patients avoid graft rejection and GVHD, making it a promising curative therapy for transfusion-dependent β-thalassemia (TDT). In this review, we introduce the development and mechanisms of CRISPR/Cas9. Recent advances on feasible strategies of CRISPR/Cas9 targeting three globin genes (HBB, HBG, and HBA) and targeting cell selections for β-thalassemia therapy are highlighted. Current CRISPR-based clinical trials in the treatment of β-thalassemia are summarized, which are focused on γ-globin reactivation and fetal hemoglobin reproduction in hematopoietic stem cells. Lastly, the applications of other promising CRISPR-based technologies, such as base editing and prime editing, in treating β-thalassemia and the limitations of the CRISPR/Cas system in therapeutic applications are discussed.
CRISPR Gene Therapy: A Promising One-Time Therapeutic Approach for Transfusion-Dependent β-Thalassemia—CRISPR-Cas9 Gene Editing for β-Thalassemia

Udani Gamage,Kesari Warnakulasuriya,Sonali Hansika,Gayathri N. Silva

DOI: https://doi.org/10.3390/thalassrep13010006

2023-02-06

Thalassemia Reports

Abstract:β-Thalassemia is an inherited hematological disorder that results from genetic changes in the β-globin gene, leading to the reduced or absent synthesis of β-globin. For several decades, the only curative treatment option for β-thalassemia has been allogeneic hematopoietic cell transplantation (allo-HCT). Nonetheless, rapid progress in genome modification technologies holds great potential for treating this disease and will soon change the current standard of care for β-thalassemia. For instance, the emergence of the CRISPR/Cas9 genome editing platform has opened the door for precision gene editing and can serve as an effective molecular treatment for a multitude of genetic diseases. Investigational studies were carried out to treat β-thalassemia patients utilizing CRISPR-based CTX001 therapy targeting the fetal hemoglobin silencer BCL11A to restore γ-globin expression in place of deficient β-globin. The results of recently carried out clinical trials provide hope of CTX001 being a promising one-time therapeutic option to treat β-hemoglobinopathies. This review provides an insight into the key scientific steps that led to the development and application of novel CRISPR/Cas9–based gene therapies as a promising therapeutic platform for transfusion-dependent β-thalassemia (TDT). Despite the resulting ethical, moral, and social challenges, CRISPR provides an excellent treatment option against hemoglobin-associated genetic diseases.
Progress of CRISPR-Cas9 in Treatment of β-thalassemia

Shenru Dai

DOI: https://doi.org/10.54097/hset.v36i.5649

2023-03-21

Abstract:β-thalassemia is a common genetic blood disorder, including three clinical and hemtological conditions: the thalassemia intermedia, β-thalassemia carrier state, and thalassemia major. It is widely distributed in the tropical, subtropical and mediterranean regions, and It has grown to be a significant global public health issue. Currently, the sole curative treatment for β-thalassemia is hematopoietic stem cell transplantation (HSCT), but the development of the HSCT is limited by the lack of an immunomatched donor and the high cost. Considering the advancement of gene editing technology in recent years, it is possible to cure the β-thalassemia with low cost and higher chances of surviving. CRISPR-Cas9 system, since its characteristics of simple operation, targeting specificity and low price, has been widely used in the field of life science and medical science. Currently, the study of CRISPR-Cas9 technology in the treatment of β-thalassemia has made a partial progress. This review systematically introduces the application of CRISPR-Cas9 technology in the treatment of β-thalassemia.

Medicine
Gene therapy and gene editing strategies in inherited blood disorders

Xuemei Song,JinLei Liu,Tangcong Chen,Tingfeng Zheng,Xiaolong Wang,Xiang Guo

DOI: https://doi.org/10.1016/j.jgg.2024.07.004

2024-07-08

Abstract:Gene therapy has shown significant potential in treating various diseases, particularly inherited blood disorders such as hemophilia, sickle cell disease, and thalassemia. Advances in understanding the regulatory network of disease-associated genes have led to the identification of additional therapeutic targets for treatment, especially for β-hemoglobinopathies. Erythroid regulatory factor BCL11A offers the most promising therapeutic target for β-hemoglobinopathies and reduction of its expression using the commercialized gene therapy product Casgevy was approved for use in the UK and USA in 2023. Notably, the emergence of innovative gene editing technologies has further broadened the gene therapy landscape, presenting new possibilities for treatment. Intensive studies indicate that base editing and prime editing, built upon CRISPR technology, enable precise single-base modification in hematopoietic stem cells for addressing inherited blood disorders ex vivo and in vivo. In this review, we present an overview of the current landscape of gene therapies, focusing on clinical research and gene therapy products for inherited blood disorders, evaluation of potential gene targets, and the gene editing tools employed in current gene therapy practices, which provides an insight for the establishment of safer and more effective gene therapy methods for a wider range of diseases in the future.
CRISPR/Cas9 in the treatment of -thalassemia

Yingrui Li

DOI: https://doi.org/10.54254/2753-8818/17/20240679

2023-12-04

Abstract:-thalassemia is a congenital hemolytic anemia, a class of hemoglobinopathies caused by a common single-gene recessive condition in which the synthesis of the chain is either totally or partially blocked. About 50% of patients have symptoms within the first three months of life. At birth, the disease is often asymptomatic, and it mostly gets worse during infancy. If left untreated, the disease usually claims its victims by the time they are five years old since its severity rises with age. Currently, there is no cure for this disease, and the main treatment is blood transfusion. With the continuous progress of medical level, gene editing technology is developing rapidly, among which CRISPR/Cas system as a gene editing technology has been applied in the research of single gene genetic disease treatment, and CRISPR/Cas9 has been widely used in the research of treating geopathic anemia because of its high efficiency, low cost, and high specificity, for example, repairing pluripotent stem cells HBB genes, inducing fetal hemoglobin expression and inhibition of HBA gene expression. This review methodically explains the development of CRISPR/Cas9 through its creation and mode of operation, various research hypotheses tested in animal studies and clinical trials, as well as analyses of safety concerns.
β-Thalassemia gene editing therapy: Advancements and difficulties

Jing Hu,Yebing Zhong,Pengxiang Xu,Liuyan Xin,Xiaodan Zhu,Xinghui Jiang,Weifang Gao,Bin Yang,Yijian Chen

DOI: https://doi.org/10.1097/md.0000000000038036

IF: 1.6

2024-05-05

Medicine

Abstract:β-Thalassemia is an inherited disorder of hemoglobin (Hb) production, resulting in ineffective erythropoiesis. [ 1 ] Chronic hemolysis is the predominant symptom, with clinical signs of myeloproliferative, extramedullary hematopoiesis, and iron homeostasis disorders. [ 1 ] Patients with thalassemia suffer from the most common monogenic hereditary disease worldwide and also represent the largest monogenic hereditary disease in China. [ 2 ] It originates from the Mediterranean, the Middle East, and Southeast Asia. The disease has a widespread distribution among populations and affects a large number of individuals, with an estimated carrier rate of the β-thalassemia gene at around 1.5% globally. [ 3 ] β-Thalassemia is classified as nontransfusion dependent β-thalassemia or transfusion-dependent β-thalassemia (TDT) on the basis of transfusion requirements. [ 4 ] Regular transfusion is the mainstay of treatment for patients with TDT; however, it brings with it iron loading related to transfusion, increased irreversible end-organ toxicity, and adverse effects of iron chelators. Hematopoietic stem cell transplantation is the only treatment, and gene editing therapy has opened the door to a cure for β-thalassemia patients. In recent years, gene editing has been developed rapidly and applied widely, such as applying mature gene-addition technology, directly repairing defective β-pearl protein genes on autologous HSCs such as zinc finger nucleases (ZFNs), transcription activator-like effector nucleases (TALENs), and especially the emerging CRISPR-Cas9 genome editing technology, or activating other genes that can replace the function of β-pearl proteins. Here, we review the emerging gene therapy modalities for the treatment of thalassemia and the possibilities for future directions.

medicine, general & internal
CRISPR-Based Gene Therapies: From Preclinical to Clinical Treatments

Marine Laurent,Marine Geoffroy,Giulia Pavani,Simon Guiraud

DOI: https://doi.org/10.3390/cells13100800

IF: 6

2024-05-08

Cells

Abstract:In recent years, clustered regularly interspaced short palindromic repeats (CRISPRs) and CRISPR-associated (Cas) protein have emerged as a revolutionary gene editing tool to treat inherited disorders affecting different organ systems, such as blood and muscles. Both hematological and neuromuscular genetic disorders benefit from genome editing approaches but face different challenges in their clinical translation. The ability of CRISPR/Cas9 technologies to modify hematopoietic stem cells ex vivo has greatly accelerated the development of genetic therapies for blood disorders. In the last decade, many clinical trials were initiated and are now delivering encouraging results. The recent FDA approval of Casgevy, the first CRISPR/Cas9-based drug for severe sickle cell disease and transfusion-dependent β-thalassemia, represents a significant milestone in the field and highlights the great potential of this technology. Similar preclinical efforts are currently expanding CRISPR therapies to other hematologic disorders such as primary immunodeficiencies. In the neuromuscular field, the versatility of CRISPR/Cas9 has been instrumental for the generation of new cellular and animal models of Duchenne muscular dystrophy (DMD), offering innovative platforms to speed up preclinical development of therapeutic solutions. Several corrective interventions have been proposed to genetically restore dystrophin production using the CRISPR toolbox and have demonstrated promising results in different DMD animal models. Although these advances represent a significant step forward to the clinical translation of CRISPR/Cas9 therapies to DMD, there are still many hurdles to overcome, such as in vivo delivery methods associated with high viral vector doses, together with safety and immunological concerns. Collectively, the results obtained in the hematological and neuromuscular fields emphasize the transformative impact of CRISPR/Cas9 for patients affected by these debilitating conditions. As each field suffers from different and specific challenges, the clinical translation of CRISPR therapies may progress differentially depending on the genetic disorder. Ongoing investigations and clinical trials will address risks and limitations of these therapies, including long-term efficacy, potential genotoxicity, and adverse immune reactions. This review provides insights into the diverse applications of CRISPR-based technologies in both preclinical and clinical settings for monogenic blood disorders and muscular dystrophy and compare advances in both fields while highlighting current trends, difficulties, and challenges to overcome.

cell biology
Targeted Gene Insertion: The Cutting Edge of CRISPR Drug Development with Hemophilia as a Highlight

Zhenjie Zhang,Siqi Zhang,Hoi Ting Wong,Dali Li,Bo Feng

DOI: https://doi.org/10.1007/s40259-024-00654-5

IF: 7.744

2024-03-17

BioDrugs

Abstract:The remarkable advance in gene editing technology presents unparalleled opportunities for transforming medicine and finding cures for hereditary diseases. Human trials of clustered regularly interspaced short palindromic repeats (CRISPR)/CRISPR-associated protein-9 nuclease (Cas9)-based therapeutics have demonstrated promising results in disrupting or deleting target sequences to treat specific diseases. However, the potential of targeted gene insertion approaches, which offer distinct advantages over disruption/deletion methods, remains largely unexplored in human trials due to intricate technical obstacles and safety concerns. This paper reviews the recent advances in preclinical studies demonstrating in vivo targeted gene insertion for therapeutic benefits, targeting somatic solid tissues through systemic delivery. With a specific emphasis on hemophilia as a prominent disease model, we highlight advancements in insertion strategies, including considerations of DNA repair pathways, targeting site selection, and donor design. Furthermore, we discuss the complex challenges and recent breakthroughs that offer valuable insights for progressing towards clinical trials.

oncology,pharmacology & pharmacy,immunology
[Advances in AAV-CRISPR/Cas9-Mediated Hemophilia A Gene Therapy --Review]

Shuai Fang,Gang Wang,Lin-Hua Yang

DOI: https://doi.org/10.19746/j.cnki.issn.1009-2137.2023.06.045

Abstract:Hemophilia A(HA) is an X-linked recessive bleeding disorder caused by mutations in coagulation factor VIII. Nowadays, exogenous coagulation factor replacement therapy is the main treatment. With the continuous development of gene therapy, new research directions have been provided for the treatment of hemophilia A. CRISPR-Cas9 technology was applied to select suitable target sites, and mediate the targeted knock-in and efficient expression of exogenous B-domain-deleted FⅧ variant gene through corresponding vectors for the treatment of hemophilia A.CRISPR-Cas9 technology is an emerging gene editing tool with great efficiency, safety and effectiveness, and has been widely used in hemophilia gene therapy research. This paper reviews the vector selection, construction of therapeutic genes, gene editing technology and selection of expression target sites for hemophilia A gene therapy at this stage.
CRISPR/Cas9-mediated genome editing: from basic research to gene therapy

Rajeev Goel

DOI: https://doi.org/10.18203/2320-6012.ijrms20241589

2024-05-31

International Journal of Research in Medical Sciences

Abstract:CRISPR/Cas9 mediated genome editing is one of the most significant molecular tools discovered to edit the desired genes. It has ushered in a new era of novel possibilities of gene therapy. CRISPR/Cas9 system was originally observed as a part of the adaptive immune system in bacteria. It later on was adapted to carry precise and targeted alterations to the DNA in human cells to be used for gene therapy to correct genetic disorders and treat various severe diseases associated with the genetic changes. Besides this, the CRISPR/Cas9 system has been employed in pharmacogenomics to develop new drugs based on the patient’s genes, in modifying the organisms for research and even for diagnostic purposes in developing CRISPR based COVID-9 test. The recent approval of a CRISPR/Cas9 cellular gene therapy by FDA named “Casgevy” to treat sickle cell anemia is a testimonial to the potentials of CRISPR/Cas9 system in developing innovative gene therapies. This review details the mechanisms of CRISPR/Cas9 gene editing and its utilization in the ongoing clinical trials in the treatment of not only the monogenic disorders like sickle cell disease, thalassemia, and genetic blindness but also in treating multi-factorial diseases like cancers, cardiac diseases, diabetes, autoimmune diseases, viral infections such as human immunodeficiency virus (HIV) etc. An attempt has also been made to discuss the various limitations, challenges and ethical frameworks encompassing CRISPR/Cas9 based gene therapy in clinical settings.
Therapeutic Gene Editing for Hemoglobinopathies

Ugo Testa,Giuseppe Leone,Maria Domenica Cappellini

DOI: https://doi.org/10.4084/MJHID.2024.068

2024-09-01

Abstract:In the last ten years, a consistent number of clinical studies have evaluated different gene approaches for the treatment of patients with sickle cell disease (SCD) and transfusion-dependent β-thalassemia (TDT). Initial studies of gene therapy for hemoglobinopathies involved the use of lentiviral vectors to add functional copies of the gene encoding β-globin in defective CD34 cells; more recently, gene editing techniques have been used involving either CRISPR-Cas9, transcription activation-like effector protein nuclease, zinc finger nuclease, and base editing to either induce fetal hemoglobin production at therapeutic levels or to genetically repair the underlying molecular defect causing the disease. Here, we review recent gene editing studies that have started the development of a new era in the treatment of hemoglobinopathies and, in general, monoallelic hereditary diseases.
Development and application of CRISPR/Cas9 technologies in genomic editing.

Cui Zhang,Renfu Quan,Jinfu Wang

DOI: https://doi.org/10.1093/hmg/ddy120

IF: 5.1214

2018-01-01

Human Molecular Genetics

Abstract:Genomic editing to correct disease-causing mutations is a promising approach for the treatment of human diseases. As a simple and programmable nuclease-based genomic editing tool, the clustered regularly interspaced short palindromic repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) system has substantially improved the ability to make precise changes in the human genome. Rapid development of CRISPR-based technologies in recent years has expanded its application scope and promoted CRISPR-based therapies in preclinical trails. Here, we review the application of the CRISPR system over the last 2 years; including its development and application in base editing, transcription modulation and epigenetic editing, genomic-scale screening, and cell and embryo therapy. Finally, the prospects and challenges related to application of CRISPR/Cas9 technologies are discussed.
CRISPR-Cas9 gene editing technology in human gene therapy: the new realm of medicine

M. S. Manasa,Manasa M. S.

DOI: https://doi.org/10.18203/2349-3933.ijam20220796

2022-03-24

International Journal of Advances in Medicine

Abstract:Gene therapy has a huge clinical relevance in the present therapeutic world and is one of the many research fields of biology which received many benefits from the recent advancements of modern clustered regularly interspaced short palindromic repeats (CRISPR)-Cas9 gene editing technology. Researchers are on the way to make significant changes in the ways of treating genetic abnormalities. An increase in the number of approved clinical trials of CRISPR based gene therapy shows we are not too far from eliminating deadly diseases such as acquired immunodeficiency syndrome (AIDS), cancer and many inherited genetic conditions from the society. However, there are some challenges associated with the development of CRISPR technology in medical field most of which revolves around its safety, efficiency and ethics. Lack of an optimized method by which the CRISPR-Cas9 expression cassette can be delivered to cells is one of the main challenges when it comes to its application in human gene therapy. Although viral vectors are the most common delivery systems used in gene therapy, recent researches show promising results on using lipid- based l delivery systems such as liposome-templated hydrogel nanoparticles (LHNPs). As these could eliminate the safety concerns of using viral vectors, it is expected to have potential therapeutic applications in future. Nevertheless, the efficiency of non-viral systems is still not fully comparable with that of viral vectors. Hence, CRISPR based therapies might take longer than expected to be prevalent in the medical field. In this short review, the recent advances of CRISPR technology in gene therapy is discussed along with its challenges and limitations.
CRISPR/Cas9 therapeutics: progress and prospects

Tianxiang Li,Yanyan Yang,Hongzhao Qi,Weigang Cui,Lin Zhang,Xiuxiu Fu,Xiangqin He,Meixin Liu,Pei-feng Li,Tao Yu

DOI: https://doi.org/10.1038/s41392-023-01309-7

IF: 39.3

2023-01-17

Signal Transduction and Targeted Therapy

Abstract:Clustered regularly interspaced short palindromic repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) gene-editing technology is the ideal tool of the future for treating diseases by permanently correcting deleterious base mutations or disrupting disease-causing genes with great precision and efficiency. A variety of efficient Cas9 variants and derivatives have been developed to cope with the complex genomic changes that occur during diseases. However, strategies to effectively deliver the CRISPR system to diseased cells in vivo are currently lacking, and nonviral vectors with target recognition functions may be the focus of future research. Pathological and physiological changes resulting from disease onset are expected to serve as identifying factors for targeted delivery or targets for gene editing. Diseases are both varied and complex, and the choice of appropriate gene-editing methods and delivery vectors for different diseases is important. Meanwhile, there are still many potential challenges identified when targeting delivery of CRISPR/Cas9 technology for disease treatment. This paper reviews the current developments in three aspects, namely, gene-editing type, delivery vector, and disease characteristics. Additionally, this paper summarizes successful examples of clinical trials and finally describes possible problems associated with current CRISPR applications.

biochemistry & molecular biology,cell biology
The power and the promise of CRISPR/Cas9 genome editing for clinical application with gene therapy

Ning Guo,Ji-Bin Liu,Wen Li,Yu-Shui Ma,Da Fu

DOI: https://doi.org/10.1016/j.jare.2021.11.018

IF: 12.822

2021-12-01

Journal of Advanced Research

Abstract:BACKGROUND: Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) is derived from the bacterial innate immune system and engineered as a robust gene-editing tool. Due to the higher specificity and efficiency of CRISPR/Cas9, it has been widely applied to many genetic and non-genetic disease, including cancers, genetic hemolytic diseases, acquired immunodeficiency syndrome, cardiovascular diseases, ocular diseases, and neurodegenerative diseases, and some X-linked diseases. Furthermore, in terms of the therapeutic strategy of cancers, many researchers used the CRISPR/Cas9 technique to cure or alleviate cancers through different approaches, such as gene therapy and immune therapy.AIM OF REVIEW: Here, we conclude the recent application and clinical trials of CRISPR/Cas9 in non-cancerous diseases and cancers and pointed out some of the problems to be solved.KEY SCIENTIFIC CONCEPTS OF REVIEW: CRISPR/Cas9, derived from the microbial innate immune system, is developed as a robust gene-editing tool and has been applied widely. Due to its high accuracy and efficiency, CRISPR/Cas9 techniques may provide a great chance to treat some gene-related diseases by disrupting, inserting, correcting, replacing, or blocking genes for clinical application with gene therapy.

multidisciplinary sciences
The Potential of CRISPR/Cas9 Gene Editing as a Treatment Strategy for Inherited Diseases

Sameh A. Abdelnour,Long Xie,Abdallah A. Hassanin,Erwei Zuo,Yangqing Lu

DOI: https://doi.org/10.3389/fcell.2021.699597

IF: 5.5

2021-12-15

Frontiers in Cell and Developmental Biology

Abstract:Clustered regularly interspaced short palindromic repeats (CRISPR) is a promising innovative technology for genomic editing that offers scientists the chance to edit DNA structures and change gene function. It has several possible uses consisting of editing inherited deficiencies, treating, and reducing the spread of disorders. Recently, reports have demonstrated the creation of synthetic RNA molecules and supplying them alongside Cas9 into genome of eukaryotes, since distinct specific regions of the genome can be manipulated and targeted. The therapeutic potential of CRISPR/Cas9 technology is great, especially in gene therapy, in which a patient-specific mutation is genetically edited, or in the treating of human disorders that are untreatable with traditional treatments. This review focused on numerous, in vivo , in vitro, and ex vivo uses of the CRISPR/Cas9 technology in human inherited diseases, discovering the capability of this versatile in medicine and examining some of the main limitations for its upcoming use in patients. In addition to introducing a brief impression of the biology of the CRISPR/Cas9 scheme and its mechanisms, we presented the utmost recent progress in the uses of CRISPR/Cas9 technology in editing and treating of human genetic diseases.

cell biology,developmental biology
Therapeutic applications of CRISPR/Cas9 system in gene therapy

Hasan Mollanoori,Shahram Teimourian

DOI: https://doi.org/10.1007/s10529-018-2555-y

2018-04-28

Biotechnology Letters

Abstract:Gene therapy is based on the principle of the genetic manipulation of DNA or RNA for treating and preventing human diseases. The clustered regularly interspaced short palindromic repeats/CRISPR associated nuclease9 (CRISPR/Cas9) system, derived from the acquired immune system in bacteria and archaea, has provided a new tool for accurate manipulation of genomic sequence to attain a therapeutic result. The advantage of CRISPR which made it an easy and flexible tool for diverse genome editing purposes is that a single protein (Cas9) complex with 2 short RNA sequences, function as a site-specific endonuclease. Recently, application of CRISPR/Cas9 system has become popular for therapeutic aims such as gene therapy. In this article, we review the fundamental mechanisms of CRISPR-Cas9 function and summarize preclinical CRISPR-mediated gene therapy reports on a wide variety of disorders.

biotechnology & applied microbiology
EcoRI methylase. Physical and catalytic properties of the homogeneous enzyme.

R. A. Rubin,P. Modrich

DOI: https://doi.org/10.1016/S0021-9258(19)66964-4

IF: 5.485

1977-10-25

Journal of Biological Chemistry

Abstract:
CRISPR/Cas9 Mechanism and Applications Progression

Shangyang Liu

DOI: https://doi.org/10.62051/b7416e56

2024-03-24

Abstract:CRISPR (short for Clustered Regularly Interspaced Short Palindromic Repeats) and the accompanying endonuclease Cas9 are potent tools for gene editing in many applied disciplines. The CRISPR/Cas9 system primarily functions through two components, in which the single guide RNA (sgRNA) directs the Cas9 protein with endonuclease activity to carry out precise DNA cleavage. The cell's inherent repair mechanisms allow it to complete the subsequent reconnection of the broken genes. Gene knock-in or knock-out can therefore be achieved via this approach. This system was typically applied to prokaryotes in early studies. Its role as a component of their defense mechanism has been thoroughly studied. With rapid development over the past ten years, this system can now be effectively used in a multitude of eukaryotic cells, including yeast cells and mammalian cells. Because of its accuracy, effectiveness, and low cost, CRISPR/Cas9 has been widely used for human disease treatment and has shown great potential in gene therapies for hereditary diseases. However, since more late-stage clinical trials are required to validate its safety, its applications still face many challenges. This review investigates the mechanism of CRISPR/Cas9-mediated gene editing technology and highlights its recent applications in Alzheimer's disease, Sickle cell disease, and Duchenne muscular dystrophy, which are difficult to treat with current approaches. Some challenges the CRISPR/Cas9 system has encountered at this stage are described, and its prospects are also examined.
Applications and challenges of CRISPR-Cas gene-editing to disease treatment in clinics

Wenyi Liu,Luoxi Li,Jianxin Jiang,Min Wu,Ping Lin

DOI: https://doi.org/10.1093/pcmedi/pbab014

2021-07-10

Precision Clinical Medicine

Abstract:Abstract Clustered regularly interspaced short palindromic repeats (CRISPR)-associated systems (Cas) are efficient tools for targeting specific genes for laboratory research, agricultural engineering, biotechnology, and human disease treatment. Cas9, by far the most extensively used gene-editing nuclease, has shown great promise for the treatment of hereditary diseases, viral infection, cancers, and so on. Recent reports have revealed that some other types of CRISPR-Cas systems may also have surprising potential to join the fray as gene-editing tools for various applications. Despite the rapid progress in basic research and clinical tests, some underlying problems present continuous, significant challenges, such as editing efficiency, relative difficulty in delivery, off-target effects, immunogenicity, etc. This article summarizes the applications of CRISPR-Cas from bench to bedside and highlights the current obstacles that may limit the usage of CRISPR-Cas systems as gene-editing toolkits in precision medicine and offer some viewpoints that may help to tackle these challenges and facilitate technical development. CRISPR-Cas systems, as a powerful gene-editing approach, will offer great hopes in clinical treatments for many individuals with currently incurable diseases.

medicine, research & experimental

[Social Security and district psychiatry].

CRISPR/Cas-based gene editing in therapeutic strategies for beta-thalassemia

CRISPR Gene Therapy: A Promising One-Time Therapeutic Approach for Transfusion-Dependent β-Thalassemia—CRISPR-Cas9 Gene Editing for β-Thalassemia

Progress of CRISPR-Cas9 in Treatment of β-thalassemia

Gene therapy and gene editing strategies in inherited blood disorders

CRISPR/Cas9 in the treatment of -thalassemia

β-Thalassemia gene editing therapy: Advancements and difficulties

CRISPR-Based Gene Therapies: From Preclinical to Clinical Treatments

Targeted Gene Insertion: The Cutting Edge of CRISPR Drug Development with Hemophilia as a Highlight

[Advances in AAV-CRISPR/Cas9-Mediated Hemophilia A Gene Therapy --Review]

CRISPR/Cas9-mediated genome editing: from basic research to gene therapy

Therapeutic Gene Editing for Hemoglobinopathies

Development and application of CRISPR/Cas9 technologies in genomic editing.

CRISPR-Cas9 gene editing technology in human gene therapy: the new realm of medicine

CRISPR/Cas9 therapeutics: progress and prospects

The power and the promise of CRISPR/Cas9 genome editing for clinical application with gene therapy

The Potential of CRISPR/Cas9 Gene Editing as a Treatment Strategy for Inherited Diseases

Therapeutic applications of CRISPR/Cas9 system in gene therapy

EcoRI methylase. Physical and catalytic properties of the homogeneous enzyme.

CRISPR/Cas9 Mechanism and Applications Progression

Applications and challenges of CRISPR-Cas gene-editing to disease treatment in clinics